Skip to main content

Table 5 Multiple Tobit regression adjusting for age (right ear)

From: Baseline audiological profiling of South African females with cervical cancer: an important attribute for assessing cisplatin-associated ototoxicity

Frequency (Hz)

No. of non-responses

Risk factors

Estimate of coefficient (SE); p-value

HIV seropositive

NCD

LFPTT

125

0

0.79 (2.78); 0.77

2.42 (2.13); 0.26

250

0

1.72 (3.26); 0.59

− 0.01 (2.50); 0.99

500

0

4.17 (4.02); 0.3

0.26 (2.56); 0.92

MFPTT

1000

1

3.52 (2.68); 0.19

− 2.52 (3.08); 0.41

2000

0

1.81 (4.52); 0.69

− 0.17 (3.46); 0.96

HFPTT

4000

0

1.93 (3.2); 0.67

1.70 (3.42); 0.62

8000

0

1.07 (5.15); 0.83

3.93 (3.94); 0.32

9000

0

4.18 (5.32); 0.43

5.06 (4.07); 0.21

EHFPTT

10,000

1

5.51 (5.84); 0.34

3.32 (4.47); 0.46

11,200

1

4.40 (6.21); 0.01

3.88 (4.76); 0.41

12,500

12 (14.6%)

8.32 (6.02); 0.16

− 5.96 (4.54); 0.38

14,000

31 (37.8%)

6.42 (6.79); 0.34

− 0.49 (5.33); 0.93

16,000

57 (70%)

0.99 (7.71); 0.89

0.76 (6.0); 0.89

18,000

75 (91%)

0.03 (3.45); 0.99

3.53 (2.99); 0.24

20,000

79 (96%)

9.58 (4.08); 0.02

− 0.26 (0.48); 0.59

  1. LFPTT, Low-frequency pure tone thresholds; MFPTT, Mid-frequency pure tone thresholds; HFPTT, High frequency pure tone thresholds; EHFPTT, Extended high-frequency pure tone thresholds; NCD, Hypertension and Diabetes